Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Tapia, Milagritos D; Findlow, Helen; Idoko, Olubukola T; Preziosi, Marie-Pierre; Kulkarni, Prasad S; Enwere, Godwin C; Elie, Cheryl; Parulekar, Varsha; Sow, Samba O; Haidara, Fadima Cheick; +14 more... Diallo, Fatoumata; Doumbia, Moussa; Akinsola, Adebayo K; Adegbola, Richard A; Kampmann, Beate; Chaumont, Julie; Martellet, Lionel; Marchetti, Elisa; Viviani, Simonetta; Tang, Yuxiao; Plikaytis, Brian D; LaForce, F Marc; Carlone, George; Borrow, Ray; (2015) Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age. CLINICAL INFECTIOUS DISEASES, 61 Sup (Suppl ). S514-S520. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/civ672

Abstract

BACKGROUND: Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. METHODS: African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA). RESULTS: Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. CONCLUSIONS: A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination. CLINICAL TRIALS REGISTRATION: ISRTCN78147026.